Earnings call transcript: Emyria posts 208% revenue jump in H2 2026

Emyria reported a staggering 208% jump in revenue for the second half of 2026, reaching just over AUD 4 million. The Australian psychedelic-therapy provider expanded rapidly, adding five operational clinics and treating 138 patients, up from 24 in the previous year. The Perth clinic reached break-even, a key milestone indicating the model's viability.

Management expects weekly dosing capacity to reach 90 days with five clinics operating, potentially hitting AUD 46.8 million in annualized revenue at full utilization. The company's strategic focus lies in Australia, the first jurisdiction with legal approval for psychedelic-assisted therapy. While the share price dipped after hours, remaining near the lower end of its 52-week range, investors seem cautiously optimistic about the company's growth trajectory.